Status:
COMPLETED
Open-Label Trial Of Oral PF-00299804 By Continuous Dosing In Patients With Recurrent Or Metastatic Head And Neck Squamous Cell Cancer
Lead Sponsor:
Pfizer
Conditions:
Head and Neck Neoplasms
Eligibility:
All Genders
18-99 years
Phase:
PHASE2
Brief Summary
This study will investigate the safety and efficacy of oral PF-00299804 in patients who have not yet undergone any other drug treatment for recurrent and/ or metastatic head and neck squamous cell can...
Eligibility Criteria
Inclusion
- Recurrent or metastatic Squamous Cell Cancer of the Head and Neck;
- Measurable disease;
- Eastern Cooperative Oncology Group (ECOG) 0-1 in Stage 1 = first 23 patients;
- Eastern Cooperative Oncology Group (ECOG) 0-2 in Stage 2 = 33 patients;
Exclusion
- prior therapy for recurrence;
- platelets \< 75,000;
- prior Epidermal Growth Factor Receptor (EGFR) therapy;
- interstitial lung disease;
- primary of nasopharynx
Key Trial Info
Start Date :
November 4 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 18 2012
Estimated Enrollment :
69 Patients enrolled
Trial Details
Trial ID
NCT00768664
Start Date
November 4 2008
End Date
April 18 2012
Last Update
February 9 2021
Active Locations (10)
Enter a location and click search to find clinical trials sorted by distance.
1
BC Cancer Agency, Vancouver Centre
Vancouver, British Columbia, Canada, V5Z 4E6
2
Fairmont Medical Building
Vancouver, British Columbia, Canada, V5Z1H7
3
Hamilton Health Sciences
Hamilton, Ontario, Canada, L8V 5C2
4
London Health Sciences Centre
London, Ontario, Canada, N6A 4L6